Given the growing evidence that various monogenic forms of neurodevelopmental disorders, such as autism spectrum disorders, childhood epilepsy, severe developmental epileptic encephalopathies, intellectual disabilities and schizophrenia, may reflect primary disorders of cIN development, migration or function, the development of cell-based therapies involving the transplantation of cIN progenitors has gained momentum. This evidence concerns the gene PDXP and developmental and epileptic encephalopathy.